ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOF

1 . An antibody that specifically binds an epitope in CD22, wherein the antibody comprises:

a) an immunoglobulin heavy chain comprising a VH region having the amino acid sequence

EVQLVESGGGLVKPGGSLX 1 LSCAASGFAFSIYDMSWVRQAPGKGLEWVAYISSGGGTT YYPDTVKGRFTISRDNAKNX 2 LYLQMX 3 SLRAEDTAMYYCARHSGYGSSYGVLFAYWG QGTLVTVSS (SEQ ID NO:1), where X 1 is K or R; X 2 is S or T; and X 3 is N or S; and

b) an immunoglobulin light chain.

2 . The antibody of claim 1 , wherein the immunoglobulin light chain comprises the amino acid sequence

(SEQ ID NO: 7; VK1)

DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAVKLLIYY

TSILHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCQQGNTLPWTFGG

GTKVEIK;

(SEQ ID NO: 8; VK2

DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAVKLLIYY

TSILHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPWTFGG

GTKVEIK;

or

(SEQ ID NO: 9; VK4)

DIQMTQSPSSVSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYY

TSILHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPWTFGG

GTKVEIK .

3 .- 4 . (canceled)

5 . An antibody that specifically binds an epitope in CD22, wherein the antibody comprises:

a) an immunoglobulin light chain comprising the amino acid sequence

(SEQ ID NO: 2)

DIQMTQSPSSX 1 SASVGDRVTITCRASQDISNYLNWYQQKPGKAX 2 KLLI

YYTSILHSGVPSRFSGSGSGTDYTLTISSLQX 3 EDFATYFCQQGNTLPWT

EGGGTKVEIK,

where X 1 is L (Leu) or V (Val); X 2 is V or P; and X 3 is Q or P; and

b) an immunoglobulin heavy chain.

6 . The antibody of claim 5 , wherein the immunoglobulin heavy chain comprises an amino acid sequence selected from:

(SEQ ID NO: 3; VH3)

EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQAPGKGLEWVAY

ISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLRAEDTAMYYCARHS

GYGSSYGVLFAYWGQGTLVTVSS;

(SEQ ID NO: 4; VH4)

EVQLVESGGGLVKPGGSLRLSCAASGFAFSIYDMSWVRQAPGKGLEWVAY

ISSGGGTTYYPDTVKGRFTISRDNAKNSLYLQMSSLRAEDTAMYYCARHS

GYGSSYGVLFAYWGQGTLVTVSS;

(SEQ ID NO: 5; VH5)

EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQAPGKGLEWVAY

ISSGGGTTYYPDTVKGRFTISRDNAKNSLYLQMNSLRAEDTAMYYCARHS

GYGSSYGVLFAYWGQGTLVTVSS;

and

(SEQ ID NO: 6; VH6)

EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQAPGKGLEWVAY

ISSGGGTTYYPDTVKGRFTISRDNAKNSLYLQMSSLRAEDTAMYYCARHS

GYGSSYGVLFAYWGQGTLVTVSS.

7 . The antibody of claim 1 , wherein (i) the light chain region and the heavy chain region are present in separate polypeptides or (ii) the light chain region and the heavy chain region are present in a single polypeptide.

8 . (canceled)

9 . The antibody of claim 1 , wherein the antibody binds the epitope with an affinity of from about 10 7 M −1 to about 10 12 M −1 .

10 . The antibody of claim 1 , wherein the heavy chain region is of the isotype IgG1, IgG2, IgG3, or IgG4.

11 . The antibody of claim 1 , wherein the antibody is detectably labeled.

12 . The antibody of claim 1 , wherein the antibody is a Fv, scFv, Fab, F(ab′)2, or Fab′.

13 . The antibody of claim 1 , wherein

i. the antibody comprises a covalently linked non-peptide synthetic polymer, optionally a poly(ethylene glycol) polymer;

ii. the antibody comprises a covalently linked lipid or fatty acid moiety

iii. the antibody comprises a covalently linked polysaccharide or carbohydrate moiety;

iv. the antibody comprises a contrast agent;

v. the antibody comprises an affinity domain; and/or

vi. the antibody comprises a covalently linked cytotoxin.

14 .- 18 . (canceled)

19 . The antibody of claim 1 , wherein the antibody is immobilized on a solid support.

20 . The antibody of claim 1 , wherein the antibody is a single chain Fv (scFv) antibody.

21 . The antibody of claim 20 , wherein the scFv is multimerized.

22 . (canceled)

23 . The antibody of claim 1 , wherein the antibody comprises a constant region amino acid sequence comprising an amino acid sequence of a sulfatase motif; wherein, optionally, the sulfatase motif is modified to comprise a 2-formylglycine (FGly) moiety.

24 . (canceled)

25 . The antibody of claim 23 , wherein the sulfatase motif is modified to comprise the 2-formylglycine (FGly) moiety and the antibody comprises a heterologous moiety covalently linked to the antibody via the FGly moiety.

26 . The antibody of claim 25 , wherein the heterologous moiety is selected from a drug, a toxin, a detectable label, a water-soluble polymer, and a synthetic peptide.

27 . A recombinant expression vector comprising a nucleotide sequence encoding the antibody of claim 1 , wherein the nucleotide sequence is operably linked to a transcriptional control element that is active in a eukaryotic cell.

28 . A pharmaceutical composition comprising:

a) the antibody of claim 1 ; and

b) a pharmaceutically acceptable carrier.

29 . The pharmaceutical composition of claim 28 , wherein the antibody is encapsulated in a liposome.

30 . A method of treating B cell malignancy in a subject, the method comprising:

administering to a subject having cancer an effective amount of the pharmaceutical composition of claim 28 .